ERLEADA® for Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

In the TITAN study in patients with metastatic castration-sensitive prostate cancer (mCSPC):

ERLEADA® + ADT reduced the risk of death by 33% vs placebo + ADT1

(Median overall survival was not estimable in either arm; HR=0.67; 95% CI: 0.51, 0.89; P=0.0053)

TITAN Publication

Review the journal article to learn more about the study results

Accessing this article may require a subscription to The New England Journal of Medicine.


ADT = androgen deprivation therapy; CI = confidence interval; HR = hazard ratio; TITAN = Targeted Investigational Treatment Analysis of Novel Antiandrogen.

Reference

1. ERLEADA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.